InnoCare Pharma (HKG:9969, SHA:688428) unit Beijing InnoCare Pharma Tech and certain other parties have entered into an exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02, a Monday Hong Kong bourse filing said.
The contract grants Prolium the exclusive right to develop, register, manufacture, and commercialize ICP-B02 globally in non-oncology fields and in global oncology fields outside of Asia.
ICP-B02 is designed to redirect and activate T-cells to eliminate tumor cells through T-cell Dependent Cellular Cytotoxicity and is undergoing clinical trials to assess its safety and efficacy.
Beijing InnoCare Pharma Tech and Keymed Biosciences' (HKG:2162) unit Keymed Biosciences (Chengdu) each own 50% rights in ICP-B02, with future revenue to be shared equally between the parties.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。